- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01687257
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
New South Wales
-
Newtown, New South Wales, Austrália
-
-
-
-
-
Barcelona, Espanha
-
-
Madrid
-
Majadahonda, Madrid, Espanha
-
-
-
-
Colorado
-
Aurora, Colorado, Estados Unidos
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos
-
-
-
-
Clichy
-
Leclerc, Clichy, França
-
-
-
-
Auckland
-
Grafton, Auckland, Nova Zelândia
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Chronic infection with Hepatitis C with HCV RNA > 1000 IU/mL
- Individuals with cirrhosis with Child-Pugh score < 10
- Esophageal or gastric varices on endoscopy within 6 months prior to or at screening
- Hepatic Venous Pressure Gradient (HVPG) > 6 mmHg
- Body mass index (BMI) ≥ 18 kg/m^2
- Naïve to all nucleotides/nucleoside treatments for chronic HCV infection
Exclusion Criteria:
- Have any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance
- HIV or chronic hepatitis B virus (HBV) infection (HBsAg positive)
- Alpha-fetoprotein (AFP) > 50 unless negative imaging for hepatic masses within the last 6 months or during screening
- Refractory ascites as defined by requiring paracentesis > twice within 1 month prior to screening
- Active variceal bleeding within 6 months of screening
- Expected survival of < 1 year
- History of hepatorenal, or hepatopulmonary syndrome.
- Evidence of renal impairment (CrCl < 50 mL/min)
- History of major organ transplantation, including liver transplant.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: SOF+RBV
Participants will receive SOF+RBV for 48 weeks.
|
Comprimidos de RBV administrados por via oral em uma dose diária dividida de acordo com as recomendações de dosagem baseadas no peso da bula (< 75 kg = 1.000 mg e ≥ 75 kg = 1.200 mg)
SOF 400 mg comprimido administrado por via oral uma vez ao dia
Outros nomes:
|
|
Experimental: Observation, then SOF+RBV
Participants will undergo 24 weeks of observation and then receive SOF+RBV for 48 additional weeks.
|
Comprimidos de RBV administrados por via oral em uma dose diária dividida de acordo com as recomendações de dosagem baseadas no peso da bula (< 75 kg = 1.000 mg e ≥ 75 kg = 1.200 mg)
SOF 400 mg comprimido administrado por via oral uma vez ao dia
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
Prazo: Posttreatment Week 12 (SOF+RBV) and up to 24 weeks (Observation)
|
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.
For the Observation/SOF+RBV group, SVR12 during the observational period was defined as HCV RNA < LLOQ for 12 consecutive weeks, any time during the observational period.
|
Posttreatment Week 12 (SOF+RBV) and up to 24 weeks (Observation)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of Participants With SVR at 4, 24, and 48 Weeks After Discontinuation of Therapy (SVR4, SVR24, and SVR48)
Prazo: Posttreatment Weeks 4, 24, and 48
|
SVR4, SVR24, and SVR48 were defined as HCV RNA < LLOQ at 4, 24, and 48 weeks after stopping study treatment, respectively.
|
Posttreatment Weeks 4, 24, and 48
|
|
Percentage of Participants Experiencing On-Treatment Virologic Failure
Prazo: Up to 48 weeks
|
On-treatment virologic failure was defined as:
|
Up to 48 weeks
|
|
Percentage of Participants Experiencing Viral Relapse
Prazo: Up to Posttreatment Week 24
|
Viral relapse was defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.
|
Up to Posttreatment Week 24
|
|
Change From Baseline in Hepatic Venous Pressure Gradient (HVPG) at End of Treatment
Prazo: Baseline; Week 24 (Observation) and Week 48 (SOF+RBV)
|
HVPG closely reflects the degree of portal hypertension in patients with cirrhosis.
The end of treatment for the Observation group was defined as the end of the observation period.
The treatment period for Group 2 was defined as the end of the observation period to the end of the treatment.
Baseline values were the last available values on or prior to first dose date of any study drug.
|
Baseline; Week 24 (Observation) and Week 48 (SOF+RBV)
|
|
Change From Baseline in Child-Pugh-Turcotte (CPT) Score
Prazo: Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)
|
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease. Data are presented as improvement, no change, or worsening in CPT scores at Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV groups). Improvement in CPT score was defined as having a decrease in CPT score from baseline, no change in CPT score was defined as having no change in CPT score from baseline, and worsening in CPT score was defined as having an increase in CPT score from baseline. Baseline values were the last available values on or prior to first dose date of any study drug. |
Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)
|
|
Change From Baseline in Model for End Stage Liver Disease (MELD) Scores
Prazo: Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)
|
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity. Data are presented as improvement, no change, or worsening in MELD scores at Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV groups). Improvement in MELD score was defined as having a baseline MELD score of 11-15 or 16-20 that changed to 0-10, or a baseline MELD score of 16-20 that changed to 11-15; no change in MELD score was defined as having no change in score group (0-10, 11-15, or 16-20) from baseline; and worsening in MELD score was defined as having a baseline MELD score of 0-10 that changed to 11-15 or 16-20, or a baseline MELD score of 11-15 that changed to 16-20. Baseline values were the last available values on or prior to first dose date of any study drug. |
Baseline; Week 24 (Observation) and Posttreatment Week 4 (SOF+RBV)
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Insuficiência Hepática
- Processos Patológicos
- Doenças cardiovasculares
- Doenças Vasculares
- Infecções por vírus de RNA
- Doenças Virais
- Infecções
- Infecções transmitidas pelo sangue
- Doenças Transmissíveis
- Doenças do Fígado
- Infecções por Flaviviridae
- Hepatite, Viral, Humana
- Hepatite
- Fibrose
- Hipertensão
- Insuficiência hepática
- Hepatite C
- Cirrose hepática
- Hipertensão Portal
- Agentes Anti-Infecciosos
- Antivirais
- Sofosbuvir
Outros números de identificação do estudo
- GS-US-334-0125
- 2012-002457-29 (Número EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .